Lead therapy Solexan™ passes first-in-human safety testing

We have successfully completed our first round of human safety testing with our lead therapeutic Solexan™ (previously referred to as GS-1).

Solexan™ is a topical therapeutic Wintermute is developing as a treatment for shingles.

Shingles presents as a debilitatingly painful and itchy rash which typically takes 2 weeks to resolve. The infection is caused by Varicella Zoster Virus, the same virus that causes chicken pox. Shingles affects 1 in 3 people in their lifetime, more commonly in elderly people.

Solexan™ was repeatedly applied to the skin of 100 healthy volunteers, half with sensitive skin, and half with normal skin.

There were no serious adverse events reported from the study. The conclusion of the study was that Solexan™ ‘did not demonstrate a potential for eliciting dermal irritation or a clinically significant potential for inducing sensitization’.

‘This is a very exciting milestone as we prepare to take Solexan™ into a clinical trial for shingles,’ says Founder and CEO Dr. Thomas Rau. The clinical trials, referred to as the ZosterEase program, are set to begin in late 2023.

Beyond shingles, we also have preclinical evidence that Solexan™ is a broad-spectrum antiviral, and may have utility in other viral diseases such as herpes.

About Wintermute Biomedical, Inc.
Wintermute Biomedical, Inc. is a biotechnology company based in both Missoula, Montana and Melbourne, Australia. It has a range of fatty acid-amino acid formulations that have varying antimicrobial agency. The group also has an FDA-approved topical antifungal that it is pursuing as a shingles therapy. Wintermute is working with several universities and research agencies to investigate other potential uses of their antimicrobial formulations.